Evaluation of antitumor activity using change in tumor size of the survivin antisense oligonucleotide LY2181308 in combination with docetaxel for second-line treatment of patients with non-small-cell lung cancer: a randomized open-label phase II study

Natale R;Blackhall F;Kowalski D;Ramlau R;Bepler G;Grossi F;Lerchenmüller C;Pinder-Schenck M;Mezger J;Danson S;Gadgeel SM;Summers Y;Callies S;André V;Das M;Lahn M;Talbot D

2014-01-01